Anita J Slomski
Abstract
An angiotensin-converting enzyme (ACE) inhibitor and β-blocker prevented cardiotoxicity associated with combination chemotherapy in women with ERBB2 (formerly HER2)–positive breast cancer, reported a trial in the Journal of the American College of Cardiology.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
An angiotensin-converting enzyme (ACE) inhibitor and β-blocker prevented cardiotoxicity associated with combination chemotherapy in women with ERBB2 (formerly HER2)–positive breast cancer, reported a trial in the Journal of the American College of Cardiology.
Key concepts: Medicine, Cardiotoxicity, Breast cancer, Chemotherapy, Internal medicine, Oncology, Cancer, Angiotensin-converting enzyme